LIBRITABS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIBRITABS (LIBRITABS).
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2C19; active metabolite desmethylchlordiazepoxide. |
| Excretion | Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination. |
| Half-life | Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment. |
| Protein binding | 85-90% bound, primarily to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg; clinical meaning: extensive tissue distribution, moderate lipophilicity. |
| Bioavailability | Oral: 85-95%; IM: 90-100%; rectal: 80-90%. |
| Onset of Action | Oral: 30-60 minutes; IV: 1-5 minutes; IM: 15-30 minutes. |
| Duration of Action | 5-8 hours for anxiolytic effect; clinical context: single dose effects last 6-8 hours, prolonged with accumulation. |
| Molecular Weight | 299.8 |
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
| Dosage form | TABLET |
| Renal impairment | GFR 10-50 mL/min: decrease dose by 25-50%; GFR <10 mL/min: avoid use or reduce by 50% and monitor for excessive sedation. |
| Liver impairment | Child-Pugh class A: no adjustment needed; class B: reduce dose by 50%; class C: avoid use or reduce by 75%. |
| Pediatric use | Children 6-12 years: 5 mg orally 2-4 times daily; not recommended under 6 years. |
| Geriatric use | Initiate at 2-2.5 mg orally 1-2 times daily; increase gradually to avoid oversedation and falls; maximum 10 mg/day. |
| 1st trimester | Avoid. Risk of congenital malformations (e.g., cleft lip/palate with first trimester exposure). |
| 2nd trimester | Avoid. Associated with fetal growth restriction and neurodevelopmental effects. |
| 3rd trimester | Avoid. Risk of neonatal withdrawal syndrome (irritability, feeding difficulties), hypotonia, and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for LIBRITABS (LIBRITABS).
| Placental transfer | Crosses placenta rapidly and extensively, with fetal concentrations similar to maternal levels. |
| Breastfeeding | Chlordiazepoxide is excreted into breast milk in low concentrations. Long-acting metabolites may accumulate in neonates, especially with chronic maternal use. Monitor infant for sedation, poor feeding, and weight gain. Alternative preferred. |
■ FDA Black Box Warning
Concomitant use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
| Serious Effects |
Hypersensitivity to chlordiazepoxide or any benzodiazepineSevere hepatic impairmentNarrow-angle glaucomaMyasthenia gravisConcurrent use of opioid analgesics (enhanced CNS depression)Breastfeeding (relative; avoid if possible)
| Precautions | Risk of respiratory depression, especially with concurrent CNS depressants, Potential for dependence and withdrawal reactions, May impair cognitive and motor function, Use with caution in patients with hepatic impairment |
| Food/Dietary | Avoid grapefruit and grapefruit juice; may increase chlordiazepoxide levels. Take with or without food; food delays absorption slightly but does not affect total bioavailability. Limit caffeine as it may counteract sedative effects. Do not consume alcohol. |
Loading safety data…
| Lactation Rating |
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Chlordiazepoxide (Libritabs) is a benzodiazepine. First trimester: Increased risk of congenital malformations (e.g., cleft lip/palate) based on some studies. Second/third trimester: Risk of fetal CNS depression, hypotonia, respiratory depression, and withdrawal symptoms (floppy infant syndrome). |
| Fetal Monitoring | Monitor maternal vital signs and level of sedation. Fetal monitoring: assess fetal growth and amniotic fluid volume. Neonatal monitoring after delivery for signs of withdrawal or CNS depression. |
| Fertility Effects | No specific human data on fertility effects. In animal studies, high doses may impair fertility. Menstrual irregularities and amenorrhea reported with chronic use. |
| Clinical Pearls | LIBRITABS (chlordiazepoxide) is a benzodiazepine used for anxiety and alcohol withdrawal. It has a long half-life (24-48 hours), reducing withdrawal symptom rebound and abuse liability compared to short-acting agents. Monitor for respiratory depression, especially in COPD or sleep apnea. Use with caution in elderly due to fall risk and paradoxical excitation. Onset of action is 30-60 minutes orally. |
| Patient Advice | Take exactly as prescribed; dependence may occur with prolonged use. · Do not drive or operate machinery until you know how this drug affects you. · Avoid alcohol completely; it can cause severe sedation and respiratory depression. · Do not stop suddenly; withdrawal symptoms (e.g., seizures, anxiety) may occur. Taper under medical supervision. · May cause drowsiness, dizziness, or blurred vision; rise slowly from sitting or lying positions. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Store at room temperature away from moisture and heat. |